Analysis Of Income And Expense [Abstract]

ABIONYX Pharma - Filing #831404

Concept 2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
Analysis of income and expense [abstract]
Revenue [abstract]
Revenue
4 640 EUR
5 252 EUR
Material income and expense [abstract]
Research and development expense
1 518 EUR
1 107 EUR
Finance income (cost)
106,000 EUR
97,000 EUR
Other operating income (expense)
97,000 EUR
23,000 EUR
Selling, general and administrative expense [abstract]
Selling, general and administrative expense
2 609 EUR
3 661 EUR
Miscellaneous other comprehensive income [abstract]
Other comprehensive income, net of tax, exchange differences on translation of foreign operations and hedges of net investments in foreign operations [abstract]
Other comprehensive income, net of tax, exchange differences on translation of foreign operations
0 EUR
23,000 EUR
0 EUR
0 EUR
0 EUR
0 EUR
23,000 EUR
0 EUR
0 EUR
0 EUR
39,000 EUR
0 EUR
0 EUR
39,000 EUR
Comprehensive income, continuing and discontinued operations [abstract]
Comprehensive income
3 575 EUR
3 985 EUR

Talk to a Data Expert

Have a question? We'll get back to you promptly.